Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
First-line venetoclax (VEN) treatment for acute myeloid leukemia (AML) has high relapse rates, with limited evidence guiding subsequent therapy sequencing. This study evaluated the effectiveness of olutasidenib (OLU) versus ivosidenib (IVO) for patients withIDH1 relapsed/refractory (R/R) AML previously treated with VEN based therapy. Outcomes were compared between a subcohort of OLU-treated patients from the 2102-HEM-101 trial and an external control arm of IVO-treated patients from the Loopback Analytics electronic health record database. Entropy balancing was applied to align key prognostic variables. Risk differences (RD) for response/TI were estimated logistic regression, and hazard ratios (HR) for OS Cox regression. Following weighting, treatment with OLU versus IVO was associated with significantly higher rates of complete response (RD: 0.25; 95%CI: 0.01, 0.49), transfusion independence (RD: 0.27; 95%CI: 0.01, 0.53), and OS (HR: 0.33; 95%CI: 0.11, 0.94). Results suggest favorable effectiveness of OLU versus IVO in this population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2025.2514894 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control arm.
Leuk Lymphoma
June 2025
Georgia Cancer Center, Augusta University, Augusta, GA, USA.
First-line venetoclax (VEN) treatment for acute myeloid leukemia (AML) has high relapse rates, with limited evidence guiding subsequent therapy sequencing. This study evaluated the effectiveness of olutasidenib (OLU) versus ivosidenib (IVO) for patients withIDH1 relapsed/refractory (R/R) AML previously treated with VEN based therapy. Outcomes were compared between a subcohort of OLU-treated patients from the 2102-HEM-101 trial and an external control arm of IVO-treated patients from the Loopback Analytics electronic health record database.
View Article and Find Full Text PDFActive versus expectant management for premature rupture of membranes at term: A randomized, controlled study.
J Int Med Res
August 2023
Department of Obstetrics and Gynaecology, Nnamdi Azikiwe University Teaching Hospital (NAUTH), Nnewi, Anambra State, Nigeria.
Objective: To compare the effects on feto-maternal outcomes of expectant versus active management for premature rupture of membranes (PROM) at term.
Methods: This was a prospective randomized (1:1) controlled study involving 86 pregnant-women who received either expectant management (n = 43) or active management with misoprostol (n = 43) for PROM at term. Primary outcome was route of delivery.
Characteristics and survival of patients with cancer with intended off-label use-a cohort study.
BMJ Open
May 2022
Medical Oncology, University Hospital Basel, Basel, Switzerland
Objective: To describe the characteristics and the survival of patients with cancer with intended off-label use (OLU) cancer treatment and reimbursement request.
Design: Cohort study using medical record data.
Setting: Three major cancer centres in Switzerland.
Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic.
Br J Surg
December 2021
Background: This study aimed to determine the impact of pulmonary complications on death after surgery both before and during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
Methods: This was a patient-level, comparative analysis of two, international prospective cohort studies: one before the pandemic (January-October 2019) and the second during the SARS-CoV-2 pandemic (local emergence of COVID-19 up to 19 April 2020). Both included patients undergoing elective resection of an intra-abdominal cancer with curative intent across five surgical oncology disciplines.
Niacin for primary and secondary prevention of cardiovascular events.
Cochrane Database Syst Rev
June 2017
Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main Street West, Hamilton, ON, Canada, L8S4L8.
Background: Nicotinic acid (niacin) is known to decrease LDL-cholesterol, and triglycerides, and increase HDL-cholesterol levels. The evidence of benefits with niacin monotherapy or add-on to statin-based therapy is controversial.
Objectives: To assess the effectiveness of niacin therapy versus placebo, administered as monotherapy or add-on to statin-based therapy in people with or at risk of cardiovascular disease (CVD) in terms of mortality, CVD events, and side effects.